A Pilot Phase 1/2a, Multicentre, Open Proof-of-concept Study on the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB) Implantation in Non-infected Delayed-Union Fractures
Latest Information Update: 27 Dec 2022
At a glance
- Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
- Indications Fracture
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors BioSenic; Bone Therapeutics
- 30 Jun 2021 Results published in Bone Therapeutics Media Release
- 30 Jun 2021 According to Bone Therapeutics, results were published in Stem Cell Research & Therapy.
- 18 Feb 2020 Status changed from active, no longer recruiting to completed.